Full-year 2025 Portfolio Receipts guidance was raised to $2.975 billion to $3.125 billion, reflecting anticipated growth of 6% to 12%, supported by portfolio strength and favorable currency movements.

Labrador Iron Ore Royalty Corp offers 8.6% high yield and an advantageous risk-reward profile. Read more to see a detailed analysis on LIFZF.

Royalty Receipts in Q4 grew by 12%, driven by strong performance in products like Evrysdi, the cystic fibrosis franchise, Trelegy, Xtandi, and Tremfya. The company generated $678 million in ...

The largest royalty-free music resource, Slip.stream, is closing the gap by empowering artists to leverage the content they create, or that influencers create for them, to elevate their social ...

Royalty Pharma reports strong Q4 and FY 2024 financial growth, with projected 2025 Portfolio Receipts between $2.9 and $3.05 billion.

Looking ahead, Arm kept its full-year guidance calling for adjusted EPS of $1.45 to $1.65 on revenue of $3.8 billion to $4.1 billion. However, it said it now expects royalty revenue to grow in the ...

Gain insights into Royalty Pharma's Q1 2025 results, featuring 12% growth in receipts, expanded pipeline, capital returns, and raised full-year guidance.